PF-Atlas › Clinical Trials › NCT00047645

A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis

Interferon-gamma 1b · Phase 3

Registry ID
NCT00047645
Phase
Phase 3
Status
Completed
Drug / intervention
Interferon-gamma 1b
Sponsor
InterMune
Start
2000-04
Enrollment
330
Locations
1

About this trial

Study GIPF-001 is phase 3 study designed to determine the safety and efficacy of IFN-g 1b administered by subcutaneous injection; compared to placebo in patients with IPF who are unresponsive to steroids. 330 patients have been enrolled and were assigned to either a IFN-g 1b group or a placebo group.

View NCT00047645 on ClinicalTrials.gov →

Explore related

All Interferon-gamma 1b trialsAll IPF trials

Related trials

Interferon-gamma 1b — NCT00047658interferon-gamma 1b — NCT00052052
Medical disclaimer. This page summarizes public trial data for NCT00047645 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.